Deerfield Management
From Wikipedia, the free encyclopedia
 | |
| Company type | Private |
|---|---|
| Industry | Investment management |
| Founded | 1994 |
| Founder | Arnold Snider |
| Headquarters | 345 Park Avenue South, New York City, New York, U.S. |
Key people | James Flynn (CEO) |
| Products | Hedge fund Venture capital Private equity Private credit |
| AUM | US$15 billion (March 2023) |
Number of employees | 175 (March 2023) |
| Website | www |
| Footnotes / references [1] | |
Deerfield Management ("Deerfield") is an American investment firm headquartered in New York City. It is focused on making public and private investments in the healthcare and biotechnology industries. Deerfield is considered to be one of the largest dedicated healthcare investment firms in the world.
Deerfield was founded in 1994 by Arnold Snider with $17 million in equity.[2][3][4][5][6] Snider was previously a pharmaceutical analyst for Kidder Peabody and then a managing director at Tiger Management making Deerfield one of the Tiger Cubs funds founded by former Tiger Management employees.[2][3][4][5]
In 2000, James Flynn joined Deerfield and would later become CEO of the firm.[2]
In 2005, Snider formally retired from Deerfield.[4][5]
In 2015, Deerfield secured $550 million for its first healthcare innovations fund, aimed at scientific advancements that could lead to new therapeutics in genetic diseases, cancer and orphan diseases.[7]
In February 2019, it was reported that Deerfield has been profitable for the last five years with four of them having double-digit gains. It had a return of 11% for 2018.[2][3]
In May 2019, Deerfield acquired 345 Park Avenue South which would become its new headquarters.[8]
In 2020, Deerfield raised $880 million for its second healthcare innovations fund, and in 2025 it raised $600 million for its third.[7]
Notable deals
In August 2015, Deerfield acquired IMRIS after it filed for Chapter 11 bankruptcy protection.[9]
In April 2017, Deerfield acquired Adeptus Health after it filed for Chapter 11 bankruptcy protection.[10]
In October 2017, Deerfield committed $50 million to the Broad Institute to promote drug discovery.[6][11]
In March 2019, Deerfield announced a strategic partnership with Harvard University to fund the development of drugs and medical treatments. Deerfield would commit $100 million to it which would be funded through a new company, Lab1636.[3][6]
In April 2020, Deerfield acquired Melinta Therapeutics by exchanging $140 million in secured debt for 100% equity of the company after it filed for Chapter 11 bankruptcy protection.[12][13]
